CA-IMAGO-BIOSCIENCES
Imago BioSciences, Inc . (“Imago”), a private clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the European Medicines Agency (EMA) granted access to its PRIME (PRIority MEdicines) scheme for IMG-7289 (bomedemstat), a lysine-specific demethylase-1 (LSD1) inhibitor, for the treatment of intermediate-2 and high-risk patients with myelofibrosis who have become intolerant of, resistant to, or are ineligible for a Janus Kinase (JAK) inhibitor. IMG-7289 is being evaluated in an open-label Phase 2 clinical trial (www.myelofibrosisclinicalstudy.com ) for the treatment of advanced myelofibrosis, a bone marrow cancer that interferes with the production of blood cells.
The PRIME initiative was launched by the EMA in 2016 to provide proactive and enhanced support to the developers of promising medicines with the view of accelerating their evaluation to reach patients faster. To be eligible for PRIME, a medicine must address an unmet medical need and show potential clinical benefit based on early trial data. Myelofibrosis is a progressive cancer in which bone marrow is gradually replaced by fibrous, scar-like tissue impairing the production of blood cells for which treatment options are limited.
"We are excited to receive PRIME designation for IMG-7289, our first LSD1 inhibitor in the clinic,” said Hugh Young Rienhoff, Jr., M.D., CEO of Imago BioSciences. “We intend to work closely with the EMA to optimize our development plans and help bring IMG-7289 to patients as quickly as possible. Myelofibrosis remains a major unmet medical need and IMG-7289 represents a potential new option for patients who don’t benefit from the current standard of care.”
The EMA reviewed IMG-7289 non-clinical and clinical data from the ongoing Phase 2 study, which demonstrated improvements in symptom scores, spleen volumes, anemia and bone marrow fibrosis. Data presented at the 25th European Hematology Association (EHA) Annual Congress demonstrated that IMG-7289 was well tolerated with no dose-limiting toxicities or safety signals. The Phase 2b study is actively enrolling in the U.S., U.K., and E.U.
About IMG-7289 (Bomedemstat)
IMG-7289 is a small molecule invented and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be essential for maturation of blood cells and vital to neoplastic stem/progenitor bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy as a single agent and in combination with other chemotherapeutic agents across a range of myeloid malignancies including leukemia and myeloproliferative neoplasms such as myelofibrosis. IMG-7289 is an investigational agent currently being evaluated in several ongoing clinical trials (ClinicalTrials.gov Identifier: NCT03136185 , NCT04254978 , NCT04262141 , NCT04081220 ). IMG-7289 has FDA Orphan Drug and Fast Track Designation for both the treatment of myelofibrosis and essential thrombocythemia, and Orphan Drug Designation for treatment of acute myeloid leukemia.
About Imago BioSciences
Imago BioSciences is a private clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes. Imago has developed a series of compounds that alter the activity and function of LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell maturation and function. Imago is advancing the clinical development of its first LSD1 inhibitor, IMG-7289, for the treatment of myeloid neoplasms including myelofibrosis, essential thrombocythemia and polycythemia vera. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com and follow us on Twitter @ImagoBioRx , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005280/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Lithium Receives Saudi Patent for Vertically Integrated Lithium Metal Battery Technology25.11.2025 14:20:00 CET | Press release
Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the Kingdom of Saudi Arabia has granted the company a foundational patent titled “Vertically Integrated Pure Lithium Metal Production and Lithium Battery Production.” This broad patent covers technology that combines lithium extraction, anode production and battery manufacturing. Pure Lithium’s Brine to Battery™ is a registered trademark in the Kingdom of Saudi Arabia, planting a strong base of intellectual property in the region. “The technology is particularly relevant to Saudi Arabia because it is one of the places in the world with lithium-containing brines, and even has an abundance of vanadium, which is used in our second-generation battery,” said Founder, Chairman and CEO Emilie Bodoin. “In order to displace today’s lithium-ion battery, our vision is to create global battery hubs with closed loop supply chains, not just in the U.S., but in the many places in the world whe
‘BLUE LOCK - TOKYO EGOIST -’ kicks off on Saturday, November 2225.11.2025 14:07:00 CET | Press release
“BLUE LOCK” voice actors Kazuki Ura and Hiroshi Kamiya were also blown away by the spectacle! A countdown to the new release was held together with over 2,000 fans gathered at the Tokyo Metropolitan Government Plaza. In its efforts to promote nighttime tourism, the Tokyo Metropolitan Government is developing new attractions that illuminate the capital after dark. As part of this initiative, projection mapping is being presented year-round on the iconic Tokyo Metropolitan Government Building No. 1, transforming its façade into a canvas of light and sound. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251121922505/en/ ©Muneyuki Kaneshiro, Yusuke Nomura, KODANSHA/BLUE LOCK Production Committee. A brand-new production inspired by the internationally popular soccer anime“BLUE LOCK”, titled BLUE LOCK – TOKYO EGOIST –, began screening on Saturday, November 22. On the first day of the screening, a mini-event was held at the Tokyo M
Infineon and HTEC Showcase Humanoid Robotic Head at Infineon’s OktoberTech™ Silicon Valley 2025 Show25.11.2025 14:00:00 CET | Press release
The demo won the Partner Innovation Award for its innovative 360° multi-sensory awareness and human-interactive robotic capabilities. The long-standing collaboration between Infineon Technologies AG and HTEC reached a new milestone this October at OktoberTech™ Silicon Valley 2025, where the two companies presented their jointly developed 360° Awareness Humanoid Robotic Head. The technology, which is a result of close partnership in embedded engineering, sensor fusion, and AI integration, captured the attention of attendees and was honored with the event’s Partner Innovation Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125008456/en/ The Humanoid Robotic Head, developed by HTEC using Infineon technologies, won the Partner Innovation Award at Infineon's OktoberTech event for its innovative 360° multi-sensory awareness and human-interactive robotic capabilities. The Robotic Head represents a major step toward more pe
Henderson Municipal Power & Light builds multigigabit FTTH network with Adtran fiber access technology25.11.2025 14:00:00 CET | Press release
News summary: Kentucky-based utility and internet provider needed a scalable solution to accelerate city-wide broadband deployment Adtran’s open intelligent access technology with Mosaic One and GLDS BroadHub® streamlines operations and boosts subscriber satisfaction AI-driven insights drive smarter service delivery and open new revenue opportunities Adtran today announced that Henderson Municipal Power & Light (HMP&L) is expanding broadband services across Henderson, Kentucky, using its open, intelligent fiber access platform. The highly scalable network leverages Adtran’s AI-powered insights to boost performance and reliability, enabling HMP&L to deliver fast, dependable multigigabit fiber-to-the-home (FTTH) services to residents and businesses. Fully integrated with Mosaic One and GLDS BroadHub® platforms, the solution simplifies network management and elevates the customer experience. The strong partnership between Adtran and HMP&L is enhancing access to digital resources, providin
How Banks and Fintech Will Verify in 2026: Regula Study25.11.2025 14:00:00 CET | Press release
Regula’s report, “What’s Reshaping IDV in Banking & Fintech: 2026 Trends and Predictions,” reveals that biometric verification has become the most attacked point in the digital identity verification (IDV) process across financial organizations. New global data shows that at least three in ten financial institutions are hit by impersonation fraud, driving a shift toward more robust identity verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125171096/en/ Survey data from Regula shows banks and fintechs align on automation and integration challenges, but diverge sharply on user-experience concerns. According to survey data from organizations in the US, UAE, Germany, and Singapore, at least three in ten banks and fintechs report biometric verification as the stage most frequently targeted by fraudsters—ahead of document checks or other onboarding steps. Many of these incidents involve AI-generated media, including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom